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Hyperglycemia is a common issue affecting inpatient care. Although this is in part because of the higher
rate of hospitalization among patients with preexisting diabetes, multiple factors complicate inpatient
glucose management, including acute stress from illness or surgery, erratic dietary intake, and con-
tribution ofmedications. It has been repeatedly demonstrated that poorly controlled blood glucose levels
are associated with negative clinical outcomes, such as increased mortality, higher rate of surgical
complications, and longer length of hospital stay. Given these concerns, there has been extensive study
of the optimal strategy for management of glucose levels, with the bulk of existing literature focusing
on insulin therapy in the intensive care unit setting. This review shifts the focus to the general adult
medical and surgical wards, using clinical guidelines and sentinel studies to describe the scientific basis
behind the current basal-bolus insulin-based approach to blood sugar management among noncritically
ill inpatients. Patient-centered clinical trials looking at alternative dosing regimens and insulin analog
and noninsulin agents, such as glucagon-like peptide-1 agonist therapies, introduce safe and effective
options in the management of inpatient hyperglycemia. Data from these studies reveal that these ap-
proaches are of comparable safety and efficacy to the traditional basal-bolus insulin regimen, and may
offer additional benefit in terms of less monitoring requirements and lower rates of hypoglycemia.
Although existing data are encouraging, outcome studies will be needed to better establish the clinical
impact of these more recently proposed approaches in an effort to broaden and improve current clinical
practices in inpatient diabetes care.
Copyright © 2017 Endocrine Society
This article is published under the terms of the Creative Commons Attribution-Non Commercial
License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hyperglycemia is very common in the inpatient setting andmay be caused by a combination of
preexisting diabetes, acute physiologic stress, and medications [1, 2]. Furthermore, hyper-
glycemia is associated with worse outcomes in the inpatient setting, such as increased
mortality, increase in surgical complications, and longer length of stay, especially in patients
not known to have diabetes [3–5]. Inpatient management of diabetes is challenging, in part
because of multiple comorbidities [3]. Patients with diabetes have increased risk of cardio-
vascular disease, renal disease, and infection, among other disorders, and this translates to
a greater incidence of hospitalization and longer length of stay compared with patients
without diabetes [3, 6, 7]. Recognizing the broad and substantial impact that diabetes and
hyperglycemia have on today’s health care has therefore prompted many studies of the
management of glucose in the inpatient setting.
Management of hyperglycemia in the intensive care unit (ICU) has been extensively
studied and reviewed [8–10]. However, less information is available on the best approach to
patients outside the ICU. As demonstrated in the 2009 Normoglycaemia in Intensive Care
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Inpatient Management of Patients With Type 2 Diabetes; SSI, sliding scale insulin; TPN, total parenteral nutrition.
Received 17 November 2016
Accepted 17 February 2017
First Published Online 22 February 2017
April 2017 | Vol. 1, Iss. 4
doi: 10.1210/js.2016-1055 | Journal of the Endocrine Society | 247–259
Evaluation and Survival Using Glucose Algorithm Regulation study, an intravenous insulin
infusion is successful atmaintaining glucose in a predetermined range in the ICU; however, it
is not practical outside of a critical care setting because of the intensity of nursing support
required [11]. In this review, we will focus on use of insulin and noninsulin agents for glu-
cose control in the general adult medical and surgical wards, highlighting outcome studies,
treatment trials, and remaining controversies inmanagement. Specific issues addressed here
will include the relationship of glucose levels to outcomes, ideal targets for glucose, and
optimal medical management of blood glucose levels.
1. Historical Perspective
In a 2004 seminal review by Clement et al. [6], the question of what constitutes optimal
glucose control was investigated. The concept of blood glucose threshold levels was addressed
in terms of mortality outcomes across different medical and surgical fields. Data collected by
Umpierrez et al. [12] from 1886 admissions found that 12% of these patients demonstrated
new hyperglycemia (defined by fasting blood glucose $126 mg/dL or random blood
glucose $200 mg/dL on two or more occasions and no history of diabetes), a finding that was
associated with an 18-fold increase in inpatient mortality compared with normoglycemic
patients. These patients were also found to have longer hospital stays, greater likelihood of
need for a critical care setting, and higher rate of transitional care. A meta-analysis by Capes
et al. [13] compared the relative risk of inpatient mortality after myocardial infarction in
patients with andwithout diabetes in relation to admission blood glucose levels. Patientswith
diabetes with admission glucose $180 mg/dL were found to have a moderately increased
relative risk at 1.7 [95% confidence interval (CI), 1.2 to 2.4] for inpatient mortality compared
with those patients with diabetes and glucose values below this threshold. Among patients
without diabetes, admission glucose values of 110 to $144 mg/dL were associated with a
substantial increase in relative risk of inpatientmortality (3.9; 95%CI, 2.9 to 5.4). Of note, the
ranges of blood glucose used in these results were based on varying cutoffs among studies
included in the meta-analysis.
Hyperglycemia has also been found to correlate with postoperative complications, and
studies have shown that controlling glucose levels improves morbidity and mortality among
surgical patients [14–20]. Based on this known association, Wang et al. [21] conducted a
cohort study with .6600 patients undergoing general and vascular surgery to investigate a
correlation between preoperative glucose and postoperative infection. The sample excluded
known patients with diabetes and those with preoperative sepsis. The study authors found
that rates of infection after surgery were significantly lower in those patients with pre-
operative glucose levels within a lower range (5.62%, P, 0.001 for glucose of 70 to 99 mg/dL)
than in thosewith levels of 100 to 139mg/dL (9.33%) and 140 to 179mg/dL (10.16%). Although
these data, and those from the Capes et al. review [13], are observational, and thus subject to
the usual limitations, they do offer a solid physiologic rational for the strong association
between hyperglycemia and poor outcomes. In addition, this association is consistent across
patient populations and disease states and includes endothelial dysfunction, impaired tissue
perfusion, prothrombotic state, increased platelet aggregation, and left ventricular dys-
function [22–26].
2. Why Insulin?
When considering how tomanage hyperglycemia, insulin is generally accepted as the primary
therapy for achieving glucose control [6] based on several studies showing an association
between insulin treatment and improved patient outcomes [18, 27]. The traditional thought
has been that this was related to the effect on blood glucose levels; however, small supporting
studies have since shown pleiotropic effects independent of glucose lowering results, in-
cluding improvedmyocardial perfusion [28], decreased blood pressure [29, 30], and decreased
heart failure [31]. With knowledgeable prescribing providers, insulin can be matched to
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rapidly changing patient needs because of dose flexibility and multiple types with different
durations of action—especially in the setting of variable and unpredictable nutrition. Because
insulin does not have drug interactions, it is particularly desirable in the hospital where
other medications are being added or discontinued rapidly.
3. Improving on Tradition
Insulin is often described in terms of its pharmacokinetic and pharmacodynamic properties
and typically categorized as basal, prandial, or correctional. Although basal insulin, meant to
match endogenous insulin production in a fasting state, describes long-acting formulations
withminimal daily variation, prandial and correctional insulins are short-acting and are used
to address glucose peaks that occur after food ingestion or to correct hyperglycemia to an ideal
range, respectively [32, 33].
Outside of the ICU, glucose has frequently been managed with correctional insulin only
(the traditional sliding scale), rather than in combination with basal insulin and prandial
insulin [34]. However, this may not be the most appropriate approach for inpatient hyper-
glycemia management, a claim supported by findings from a prospective cohort study by
Queale et al. [35]. Using data from 171 medical inpatients with diabetes, study investigators
discovered that individuals receiving monotherapy with correctional insulin had a threefold
higher risk of hyperglycemia than those not on any pharmacologic diabetes treatment
(P , 0.05). Although conclusions are limited from this observational study, the data did
demonstrate a lack of benefit from regimens using only sliding-scale insulin, and subsequent
studies have since provided additional evidence supporting newer, alternative regimens.
One such study is the 2007 Randomized Study of Basal-Bolus Insulin Therapy in the
Inpatient Management of Patients With Type 2 Diabetes (RABBIT 2 Trial), a prospective
controlled investigation by Umpierrez et al. [36] comparing the efficacy and safety of a basal-
bolus regimen with the traditional sliding-scale regimen using correctional doses of insulin in
130 insulin-naive patients with known type 2 diabetes admitted to general medicine services
(ICU patients were excluded). Patients were randomized to a regimen consisting of daily
glargine and mealtime glulisine with correctional glulisine (basal bolus) using weight-based
initial dosing and a titration algorithm or glulisine only for correction of blood sugars
according to a sliding scale insulin (SSI). The study authors found that those patients in the
basal-bolusgrouphad lower fastingblood sugars (147636mg/dLvsSSI165641mg/dL,P,0.01),
lower lengths of stay, and greater prevalence of achieving goal glucose levels (blood sugar 70 to 140
mg/dL) with 66% at goal within the basal-bolus regimen as compared with 38% in the SSI group.
Incidence of hypoglycemia, defined as blood sugar,60 mg/dL, was equal between the two groups
and acceptably low at two patients each. Although admittedly underpowered to determine change
in other outcomes, such as mortality, this study did demonstrate greater glycemic control without
increased hypoglycemia in the basal-bolus group.
A follow-up study in 2011 by Umpierrez et al. [7] again compared the efficacy of a basal-
bolus regimen to a sliding-scale protocol, this time among surgical patients, with end points
including postoperative complications (wound infection, pneumonia, bacteremia, and re-
spiratory or acute renal failure) in addition to daily blood glucose levels. Unlike those patients
in the original RABBIT 2 trial, participants in RABBIT 2 surgery were not necessarily
insulin-naive. Target glucose range was 100 to 140 mg/dL in this study. In addition to
finding lower blood glucose levels in the basal-bolus group (145 6 32 mg/dL compared with
172 6 47 mg/dL in the sliding-scale group), study authors found a substantial reduction in
composite outcomes, which included pneumonia, bacteremia, wound infection, and re-
spiratory and renal failure, from those on the sliding-scale regimen (24.3%) compared with
those on the basal-bolus regimen (8.6%) (P = 0.003). This is the only randomized trial looking
at hard outcomes beyond glucose control outside of the ICU setting. There was a higher
incidence of mild hypoglycemic events in this study compared with the RABBIT 2 medicine
trial, with 23.1% of patients in the basal-bolus group and 4.7% of patients in the sliding-scale
group having a recorded glucose level ,70 mg/dL (P , 0.001). Severe hypoglycemia
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(glucose ,40 mg/dL) occurred in 3.8% of the basal-bolus group and in none of the SSI group.
Possible explanations for this higher rate compared with the medicine trial include reduced
nutritional intake among surgical patients, and most patients in the surgical trial were on a
higher total daily dose of insulin (0.5 U/kg/d compared with 0.4 U/kg/d, respectively) than
most of the patients in the medicine trial.
In the Basal Plus trial, Umpierrez et al. [37] investigated the necessity of scheduled
prandial insulin for inpatient glycemic control. The study looked at 375 patients admitted
to medical or surgical services with a known history of type 2 diabetes who were randomly
assigned to three treatment arms: a basal-bolus regimen with scheduled premeal and cor-
rective short-acting glulisine in addition to long-acting glargine, a basal plus regimen con-
sisting of glargine along with corrective glulisine, and a third arm using a corrective scale for
blood glucose levels .140 mg/dL without basal insulin. Patients were targeted to blood
glucose goal range of 100 to 140 mg/dL, and if treatment failure was encountered in the basal
plus or corrective scale group (defined as a mean daily blood glucose .240 mg/dL or con-
secutive blood glucose levels .240 mg/dL), patients were advanced to the basal-bolus reg-
imen. The study found that both the basal-bolus and basal plus regimens had lower mean
daily blood glucose levels than the corrective-only regimen (P = 0.04) and that the im-
provement in mean daily blood glucose after the first day of treatment was similar between
the two basal-containing regimens. These two regimens also were found to have less
treatment failure than the corrective regimen. There was no difference among the three
groups regarding incidence of severe hypoglycemia (defined as blood glucose ,40 mg/dL);
however, mild hypoglycemia (blood glucose ,70 mg/dL) was higher in the basal-bolus reg-
imen (16%) than the basal plus (13%) and corrective-only regimens (3%, P = 0.02). Given the
similar efficacy between the two basal-containing regimens, and overall improvement in
glycemic control relative to the corrective insulin regimen, the study concluded that basal
insulin should be included in glucose treatment plans and that a modified regimen such as
basal plus offers similar control compared with the traditional basal-bolus regimen.
Haw et al. went on to investigate the effect of these two regimens on glycemic variability
(GV), calculated using the mean daily standard deviation of blood glucose values, the mean
daily range of blood glucose (average daily GV), and the mean amplitude of glycemic ex-
cursions [38–41] in a post hoc analysis of the Basal Plus trial [42]. Looking at data from 279
general medicine and surgery patients, the analysis revealed no substantial difference in GV
between the basal plus and basal-bolus groups. Interestingly, surgical patients in the basal-
bolus group compared with their surgical cohort in the basal plus group were found to have
a statistically significant higher GV. Of note, the degree of GV did not seem to correlate with
the rate of hospital complications; therefore, its clinical significance is not established.
4. Human or Analog
Recombinant human insulins are available in short-acting and intermediate-acting formu-
lations. However, they are not as well matched to basal and prandial needs as the newer
analog insulins, which are available in more rapid-acting and longer-acting formulations, the
latter of which avoids the insulin peak that often complicates glucose management. Analog
insulins are, however, more expensive than their human insulin counterparts, thus creating
a dilemma for hospitals. These different factors must all be considered to determine the best
types of insulin for inpatient use. In a multicenter trial of 130 patients admitted to a general
medicine service, the safety and efficacy of a regimen using insulin analogs was compared
with one using human insulins [43]. For this study, patients with type 2 diabetes and blood
glucose levels between 140 and 400 mg/dL were randomized to either a basal-bolus (analog
insulins) regimenwith daily detemir and premeal aspart or a split-mixed protocol using twice-
daily injections of neutral protamine Hagedorn (NPH) and regular insulin (human insulins).
Initial dosing was based on a weight-based regimen for both groups. Patients were restricted
to those with blood glucose levels between 140 and 400 mg/dL, at least a 3-month known
history of type 2 diabetes, and absence of diabetic ketoacidosis. By treating to goal blood
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glucose levels between 60 (threshold for hypoglycemia) and 140 mg/dL, study authors dis-
covered similar glycemic improvement between the detemir and NPH groups, with pre-
treatment blood glucose levels of 2286 54 mg/dL and 2236 58 mg/dL (P = 0.61) improving to
160 6 38 mg/dL and 158 6 51 mg/dL (P = 0.8), respectively, after the first day of therapy. In
addition, no significant difference was found between the two groups in terms of number of
patients experiencing an episode of hypoglycemia (P = 0.20) and frequency of hypoglycemic
blood glucose readings (P = 0.86). Based on these findings, the study authors concluded there
were no statistical differences in efficacy, as measured by improvement in mean daily blood
glucose levels, or safety, as determined by hypoglycemia incidence, between the analog
regimen of detemir/aspart and a human insulin regimen of NPH/regular. This study had
important implications for hospitals concerned with higher cost of analog insulins.
5. Hypoglycemia
Turchin et al. [44] looked at the effect inpatient hypoglycemic events had on patients in a 2009
retrospective, cohort study of 4368 admissions in 2500 patients with diabetes. Both the
number and severity of hypoglycemic events, defined as a glucose level ,50 mg/dL, were
evaluated, as were length of stay and mortality (inpatient and 1-year after discharge). The
study found a 7.7% incidence of hypoglycemia among the admissions and, through a mul-
tivariable analysis, discovered that each additional day with hypoglycemia was associated
with an 85.3% increase in odds of an inpatient death (P = 0.009); this risk rose three times for
every 10mg/dL decrease in the lowest blood glucose during hospitalization (P = 0.0058). There
was also a 65.8% increase in odds of death within 1 year after discharge (P = 0.0003) with each
additional day of hypoglycemia. As for length of stay, this was increased by 2.5 days for
each day with hypoglycemia (P , 0.0001). Further, multiple studies have also demonstrated
a positive association between mortality and hypoglycemia [45–47].
Although the mechanism behind the relationship between hypoglycemia and mortality
remains unclear, possible explanations include the proinflammatory state of hypoglycemia
and sympathetic nervous stimulation, subsequently leading to arrhythmias and ischemia [46,
48, 49]. Furthermore, the context of hypoglycemia may be important, with several studies
finding highermortality rates associatedwith spontaneous hypoglycemia comparedwith that
induced with insulin therapy [50–52]. This suggests underlying severe illness, such as
multiorgan failure, is contributing to these higher rates. Finally, in severe hypoglycemia,
neurologic complications such as seizure with aspiration may cause additional damage [53].
A retrospective cohort study by Garg et al. [54] went on to investigate whether the re-
lationship between hypoglycemia and mortality was associated with insulin use. Using in-
patient data from 2008 to 2010, the study authors examined the prevalence of mortality
across four separate groups, according to presence of hypoglycemia (defined as blood
sugar#50mg/dL) and treatment with insulin. Study findings were notable for a significantly
higher mortality among those patients with insulin-treated hypoglycemia compared with the
insulin-treated controls (20.3 vs 4.5%, P , 0.0001). Noninsulin-treated hypoglycemia was
similarly associated with greater mortality than seen among noninsulin-treated controls
(34.5 vs 1.1%, P, 0.0001). Interestingly, those in the noninsulin-treated hypoglycemia group
experienced higher mortality rates than those in the insulin-treated hypoglycemia group
(P , 0.0001); however, the opposite was found among the controls, with significantly lower
mortality in the noninsulin-treated control group compared with the insulin-treated control
group (P , 0.0001). These findings demonstrate an association between hypoglycemia and
mortality and go on to illustrate a stronger effect of spontaneous (noninsulin treated) hy-
poglycemia onmortality compared with insulin-associated hypoglycemia. This latter finding,
which has been described previously, may be the result of other contributing factors, such as
malnutrition or malignancy, in cases of spontaneous hypoglycemia that could account for a
worse prognosis.
The risk of hypoglycemia in relation to the particular regimen insulin dosing was then
assessed in a retrospective, case-control study by Rubin et al. [55] in 2011. Of 1990
doi: 10.1210/js.2016-1055 | Journal of the Endocrine Society | 251
hospitalized patients with a diagnosis of diabetes selected for the study, half were defined as
cases, as determined by a point-of-care (POC) glucose ,70 mg/dL after the first 24 hours of
admission. Controls were defined by a POC glucose $70 mg/dL and matched to each case on
the basis of hospital day of hypoglycemia, age, sex, and body mass index. The insulin doses
administered during the 24-hour period prior to hypoglycemia in the cases, andmatched POC
in the controls, were then evaluated in terms of dose per body weight and type of insulin
exposure. The latter was categorized among four different regimens: glargine plus any other
insulin, NPH plus any other insulin, lispro and/or regular insulin only, and no insulin. The
authors found that the odds of hypoglycemia (adjusted for insulin regimen, SSI use, and
albumin, creatinine, and hematocrit) were not increased by increasing insulin dosing within
a range of 0.2 to 0.6 U/kg/d. However, odds of hypoglycemia were higher among patients
receiving insulin doses .0.6 U/kg/d.
6. Noninsulin Agents: Why Not?
In addition to these observed benefits, insulin has also been the longstanding preferred agent
to treat inpatient hyperglycemia because of limitations of other therapies. Metformin,
although a recommended first-line medication for treatment of type 2 diabetes [56], is dis-
couraged in patients with conditions that predispose toward central hypoxia, such as pul-
monary, cardiac, or renal impairment, because of the concern for increased risk of lactic
acidosis, a rare but serious complication ofmetformin therapy [57]. Other contraindications to
metformin use include severe liver disease, alcohol abuse, and concurrent use of potentially
renal toxic intravenous radiographic contrast agents, all of which limit its applicability in
the hospital setting [58, 59].
Sulfonylureas are another commonly used oral agent for type 2 diabetes; however, because
insulin secretagogues, these medications can cause hypoglycemia, and unlike insulin, their
dosing is less flexible, and onset and duration of action can be less predictable. Considering
the risk of hypoglycemia is increased in those with erratic or poor oral intake, or those with
hepatic or renal impairment, all of whichmay be encounteredmore frequently in hospitalized
patients, sulfonylureas are not considered preferred agents for inpatient glycemic control
[2, 56, 57]. Thiazolidinediones, which act as insulin sensitizers, have a substantial delay in
onset of action [56]. These drugs are associated with peripheral edema and precipitation or
exacerbation of heart failure [57]. Considering these described limitations for treatment
alternatives, insulin established itself as the recommended and most widely used agent for
glucose management in the hospitalized setting [6].
7. Newer Noninsulin Agents: Maybe?
Given the detrimental effects of hypoglycemia related to insulin therapy and the complexity of
administration, studies have also been conducted looking at the role of alternatives to in-
sulin for inpatient diabetes management. Although studies looking at clinical outcomes with
incretin therapy in the hospitalized setting are limited, existing trial data suggest this may
be a useful addition to or substitute for insulin treatment. A pilot study in 2013 investigated
the safety and efficacy of sitagliptin, a DPP4 inhibitor, compared with insulin regimens in
general medical/surgical wards [60]. In this trial, 90 patients with diabetes were randomized
to one of three arms: sitagliptin only, sitagliptin with daily glargine, and a traditional basal-
bolus regimen with daily glargine and bolus lispro insulin. In addition, patients across all
three arms received correctional lispro insulin according to a standard sliding scale. Similar
improvement was seen across all three groups, including no differences in mean daily blood
glucose levels after the first day of treatment (P = 0.23) and number of readings within goal
blood glucose of 70 to 140mg/dL (P = 0.53). There was no difference in length of stay (P = 0.78)
or hypoglycemic events (P = 0.86) among the three arms, and total daily dose and number
of injections were significantly less in the sitagliptin and insulin arm compared with the
traditional basal-bolus group (P , 0.001). Of note, inclusion in this study was limited to
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patients treated for their diabetes with diet alone, oral agents, or insulin therapy at a daily
dose #0.4 U/kg, thus narrowing the clinical applicability of the study findings.
More recently, Pasquel et al. [61] went on to further investigate the role of sitagliptin
therapy in inpatient management of glucose control among inpatients with type 2 diabetes
admitted to general medicine and surgery wards. In this randomized controlled trial, 277
patients were assigned on a 1:1 basis to either the sitagliptin-basal group (daily sitagliptin
plus daily glargine) or a more conventional basal-bolus group (mealtime lispro or aspart plus
daily glargine). Study investigators found that patients in the sitagliptin-basal group had a
similar mean daily blood glucose concentration as those in the basal-bolus group (172 vs
170 mg/dL, respectively), with nonsignificant differences in treatment failure or hypogly-
cemia rate between the two groups, thus meeting the noninferiority threshold for this trial.
The utility of incretin-based therapy is further supported in an editorial by Schwartz and
DeFronzo in 2013 addressing the use of glucagon-like peptide-1 (GLP-1) receptor agonist
therapy [62]. Although long considered the gold standard for inpatient management of di-
abetes by many, Schwartz and DeFronzo proposed that the association of insulin with hy-
poglycemia and data showing lack of mortality benefit call this role of insulin into question.
They argue that, in contrast, GLP-1 agonist therapy would not carry a similar hypoglycemia
risk because of the glucose-mediated stimulation of insulin release and inhibition of gluca-
gon secretion [63, 64]. Of note, this opinion is founded on studies among critically ill patients,
and its relevancy in the non-ICU setting is less clear.
In terms of efficacy, multiple studies have found treatment with GLP-1 or GLP-1 receptor
agonist therapy is comparable with insulin in terms of glycemic control, and even allows for
lower insulin dosing if these medications are used concurrently [65–69]. Studies also suggest
an impact of GLP-1 therapy on several cardiovascular parameters, including improved left
ventricular ejection fraction and endothelial function [70–72]; however, other studies have
failed to show a similar effect on left ventricular ejection fraction [69, 73]. Given the dearth of
trials looking at clinical outcomes, further study is needed looking at GLP-1 receptor agonist
therapy among hospitalized patients. Thus far, however, data regarding incretin-based
therapy support the use of these agents for achieving glycemic control in the inpatient
setting, especially considering the additional benefit of reduced provider burden in terms of
less frequent glucose monitoring and dose titrations [74].
8. Special Circumstances
The use of enteral or parental feeding poses an additional challenge to inpatient glycemic
control, with hyperglycemia commonly associated with these forms of nutrition. This has, in
turn, been linked to greater inpatient mortality as demonstrated by a prospective study by
Olveira et al. [75], which looked at mortality rates among noncritically ill inpatients across 19
hospitals in Spain receiving total parenteral nutrition (TPN). After adjusting for multiple
factors, including nutritional state, presence of diabetes, and insulin or steroid use, logistic
regression analysis of data collected from 605 patients showed that mean blood glucose
levels .180 mg/dL while receiving TPN were associated with a 5.6 times greater mortality
risk than levels ,140 mg/dL (95% CI, 1.47 to 21.4 mg/dL). For treatment, adding regular
insulin to TPN has been a successful strategy to control hyperglycemia, and recommended
formulas for calculating dosing are available [76].
Management of hyperglycemia associated with continuous enteral feedings has proven
challenging, and few studies are available. However, one was a randomized controlled trial
conducted by Korytkowski et al. [77]. For this trial, a regimen of sliding-scale regular insulin
alone was compared with one with sliding-scale regular insulin and glargine, with 25 in-
patients randomized to each group. Although glycemic control was similar between the two
groups, 12 patients receiving only sliding-scale regular insulin required the addition of NPH
insulin because of persistent hyperglycemia, an intervention not needed among any of those
in the group also receiving glargine. Total daily insulin doses were similar between the
groups, as was frequency of hypoglycemia. These results support the role of longer-acting
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basal insulin in the management of blood glucose levels among those patients receiving
enteral feeding.
Another common factor complicating management of blood sugar among hospitalized
patients is the prevalent use of glucocorticoids as treatment of a host of conditions known to
be associated with hyperglycemia even among those without diabetes [78, 79]. To better
characterize the insulin needs of this population, Spanakis et al. [80] conducted a chart review
of 58 hospitalized patients with diabetes and found that, independent of age, race, body
weight, renal function, or disease type, among several other variables, over half the patients
remained hyperglycemic throughout their admission (n = 38). Those patients that did achieve
normoglycemia had similar requirements for basal insulin as those who remained hyper-
glycemic (23.6 vs 20.1 U, respectively; P = 0.35). However, their nutritional insulin re-
quirements were significantly higher (45.5 vs 20.1U,P, 0.001), with lower correction insulin
needs (5.8 vs 13.0 U, P, 0.001) than their hyperglycemia counterparts, respectively. Overall,
their total daily doses of insulin were similar per kilogram between the two groups. Although
limited by sample size, and because formal insulin dosing studies have not yet been per-
formed, these findings do suggest nutritional insulin, as opposed to correction, should be
made a priority when determining regimens for glucose management in patients on gluco-
corticoid therapy.
9. Moving Forward
Current guidelines based on studies presented here suggest maintaining fasting glucose
values in the 100 to 140 mg/dL range and nonfasting levels ,180 mg/dL [1]. Although the
clinical impact of hyperglycemia among hospitalized patients has been well established, with
multiple studies demonstrating increased morbidity and mortality [12, 81–83], the optimal
medical management of diabetes in the inpatient setting has been extensively studied, but
not yet definitively established [1, 2, 6, 84]. Insulin is still considered themainstay of treatment
of inpatient glucose control [85], and several trials have been conducted evaluating different
regimens, with most data supporting the use of basal insulin (either analog or human) along
with either prandial and correctional boluses compared with sliding scale only as described in
the Basal Plus trial [7, 36, 37, 43]. More data are needed, however, looking at the clinical
outcomes for insulin therapy, including patients without known diabetes. Given the known
association of insulin with hypoglycemia, and the detrimental effect such episodes have on
morbidity and mortality [44, 86], along with concerns regarding the rigorous blood sugar
monitoring and dose adjustments required with insulin therapy [74], the utility of insulin
alternatives has been investigated. Metformin, sulfonylureas, and thiazolidinediones have a
number of contraindications to use, which often limit their utility in the inpatient setting
with critically ill patients [56–58]. Incretin-based therapies have demonstrated promising
results toward glycemic control without associated hypoglycemia, and further randomized
controlled trials, specifically looking at the role of GLP-1 receptor agonist therapy, are war-
ranted [62, 64, 73, 74, 85, 87, 88]. Thus far, however, there are no long-term data regarding the
safety of incretin-based treatment. This raises the question of how effectively risk-benefit ratios
can be compared between this therapy and insulin, which benefits from decades of safety data.
Given the known negative impact of hypoglycemia and demonstrated association of hypo-
glycemia with insulin, there is an increased urgency to exploring this question.
One approach to achieving target glycemic control that is gaining attention is an auto-
mated closed-loop system for insulin delivery. Also known as the artificial pancreas, this
delivery system uses a computerized algorithm by which insulin is either increased or de-
creased according to subcutaneous glucose sensors. Thabit et al. [89] investigated the safety
and efficacy of this system compared with traditional subcutaneous insulin delivery in a 2017
controlled trial. For this study, 40 general ward inpatients with type 2 diabetes on insulin
therapy were randomized on a 1:1 basis to treatment with the closed-loop insulin delivery
system or conventional therapy according to local clinical guidelines. After a 72-hour period,
59.8% of time in the closed-loop systemwas spent in the target glucose range (100 to 180mg/dL)
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compared with 38.1% in the conventional control group. This led study investigators to
conclude that the artificial pancreas was indeed a safe and effective alternative to traditional
subcutaneous therapy among noncritically ill inpatients with type 2 diabetes receiving in-
sulin; however, additional factors warrant consideration before translating these findings to
amore realistic clinical setting. As described in an editorial response byRayman [90], barriers
to applying the closed-loop system to inpatient practice include limited familiarity among
health care professionals with this intervention and potential safety issues that may arise
with larger populations and over a longer period of time. Nevertheless, this trial serves as
another example of the promising trajectory of inpatient diabetesmanagement, and the value
in continuing to investigate additional and alternative approaches to our traditional approach
with insulin.
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